Managing Lipid Therapy
Guides statin selection and intensity with ASCVD risk calculation and LDL targets.
Why This Skill Exists
Atherosclerotic cardiovascular disease (ASCVD) remains the leading cause of death globally. The 2018 AHA/ACC Cholesterol Guideline and 2022 ACC Expert Consensus Decision Pathway define a risk-based approach to lipid management, with LDL-C as the primary target. Landmark trials (4S, HPS, JUPITER, FOURIER, ODYSSEY) demonstrate that each 39 mg/dL reduction in LDL-C reduces major cardiovascular events by approximately 22%.
Despite this, statin therapy remains underutilized — fewer than 50% of eligible patients receive appropriate-intensity statins, and escalation to ezetimibe, PCSK9 inhibitors, or bempedoic acid when LDL remains above target is inconsistent. This skill ensures systematic risk assessment, appropriate statin intensity selection, and evidence-based escalation when targets are not met.
Checkpoint A: Pre-Draft Intake (Mandatory)
- Does the patient have clinical ASCVD (prior MI, stroke, TIA, PAD, coronary revascularization)? (default: "ASCVD status not documented")
- What is the fasting lipid panel — TC, LDL-C, HDL-C, triglycerides? (default: "Lipid panel not provided")
- What is the patient's 10-year ASCVD risk score (Pooled Cohort Equations)? (default: "Not yet calculated")
- Is the patient currently on lipid-lowering therapy? If so, which agent and dose? (default: "Current therapy not documented")
- Are there statin-related side effects reported (myalgia, hepatotoxicity, new-onset DM)? (default: "No side effects reported")
- What are the risk-enhancing factors — family history of premature ASCVD, LDL ≥ 160, metabolic syndrome, CKD, inflammatory conditions, ethnicity, Lp(a), hsCRP? (default: "Risk enhancers not assessed")
- Has coronary artery calcium (CAC) scoring been performed? (default: "CAC not obtained")
- Is the patient diabetic? Age range? (default: "Diabetes status not documented")
Documents to Request
- Fasting lipid panel (recent, within 4–12 weeks of assessment)
- Prior lipid panels for trend analysis
- 10-year ASCVD risk score calculation
- CAC score report if obtained
- Current medication list
- History of statin intolerance documentation
- Lp(a) level if available
- hsCRP if available
- HbA1c (diabetes status)
- Hepatic function panel (baseline before statin initiation)
Step 1: Patient Risk Category Classification
2018 ACC/AHA Risk Groups:
| Risk Group |
Definition |
Primary Therapy |
| Clinical ASCVD |
Prior MI, stroke, TIA, PAD, coronary revascularization |
High-intensity statin; LDL < 70 |
| Very high-risk ASCVD |
ASCVD + multiple major events or high-risk conditions |
Max statin + ezetimibe ± PCSK9i; LDL < 55 |
| Severe hypercholesterolemia |
LDL ≥ 190 mg/dL |
High-intensity statin without risk calculation |
| Diabetes (age 40–75) |
DM + LDL 70–189 |
Moderate-to-high intensity statin based on risk |
| Primary prevention (age 40–75) |
No ASCVD, no DM, LDL 70–189 |
Based on 10-year ASCVD risk |
10-Year ASCVD Risk Thresholds (Primary Prevention):
| Risk Level |
10-Year Risk |
Recommendation |
| Low |
< 5% |
Lifestyle; statin generally not indicated |
| Borderline |
5–7.4% |
Consider statin if risk enhancers present |
| Intermediate |
7.5–19.9% |
Moderate-intensity statin; consider CAC for shared decision-making |
| High |
≥ 20% |
High-intensity statin |
Risk-Enhancing Factors (tip the balance toward statin initiation):
- Family history of premature ASCVD (♂ < 55, ♀ < 65)
- Persistently elevated LDL ≥ 160 mg/dL
- Metabolic syndrome
- CKD (eGFR 15–59)
- Chronic inflammatory conditions (RA, psoriasis, HIV)
- South Asian ancestry
- Premature menopause (< 40 years)
- Preeclampsia history
- Lp(a) ≥ 50 mg/dL (or ≥ 125 nmol/L)
- hsCRP ≥ 2.0 mg/L
- ABI < 0.9
Step 2: Statin Selection and Intensity
High-Intensity Statins (≥ 50% LDL reduction):
| Agent |
Dose |
| Atorvastatin |
40–80 mg |
| Rosuvastatin |
20–40 mg |
Moderate-Intensity Statins (30–49% LDL reduction):
| Agent |
Dose |
| Atorvastatin |
10–20 mg |
| Rosuvastatin |
5–10 mg |
| Simvastatin |
20–40 mg |
| Pravastatin |
40–80 mg |
| Lovastatin |
40–80 mg |
| Fluvastatin XL |
80 mg |
| Pitavastatin |
1–4 mg |
Drug Interactions to Check:
- Simvastatin: contraindicated with strong CYP3A4 inhibitors (clarithromycin, itraconazole, HIV protease inhibitors); max 20 mg with amiodarone, amlodipine
- Atorvastatin: dose limit with cyclosporine, clarithromycin, itraconazole
- Rosuvastatin: preferred in patients on CYP3A4 inhibitors (metabolized by CYP2C9)
- All statins: caution with gemfibrozil (rhabdomyolysis risk)
Step 3: LDL-C Target Assessment and Escalation
LDL-C Targets by Risk Category:
| Category |
LDL-C Target |
Threshold for Adding Non-Statin |
| Very high-risk ASCVD |
< 55 mg/dL |
LDL ≥ 55 on max statin |
| Clinical ASCVD |
< 70 mg/dL |
LDL ≥ 70 on max statin |
| High-risk primary prevention (≥ 20%) |
≥ 50% LDL reduction |
If not achieving ≥ 50% reduction |
| Diabetes with risk factors |
< 70 mg/dL |
LDL ≥ 70 on statin |
Escalation Ladder (add sequentially if LDL not at target):
- Maximize statin intensity (atorvastatin 80 mg or rosuvastatin 40 mg)
- Add ezetimibe 10 mg (additional 15–20% LDL reduction; IMPROVE-IT trial)
- Add PCSK9 inhibitor: evolocumab 140 mg SC q2 weeks or alirocumab 75–150 mg SC q2 weeks (additional 50–60% LDL reduction; FOURIER, ODYSSEY trials)
- Consider bempedoic acid 180 mg daily (additional 15–18% LDL reduction; CLEAR Outcomes trial) — particularly useful in statin-intolerant patients
- Consider inclisiran 284 mg SC (at months 0, 3, then q6 months) for sustained LDL lowering
Recheck lipid panel 4–12 weeks after any therapy change.
Step 4: Managing Statin Intolerance
True vs. Perceived Statin Intolerance:
- True myopathy: CK elevation > 10× ULN with symptoms → discontinue immediately
- Statin-associated muscle symptoms (SAMS): myalgia without significant CK elevation → most common reason for discontinuation
Approach to SAMS:
- Hold statin for 2–4 weeks (washout)
- Rechallenge with a different statin at low dose (rosuvastatin 5 mg or pravastatin 20 mg)
- Try alternate-day dosing (rosuvastatin or atorvastatin — long half-lives permit this)
- If intolerant to ≥ 2 statins: document as "statin-intolerant"
- Use non-statin therapies: ezetimibe ± bempedoic acid ± PCSK9i
CoQ10 supplementation: Mixed evidence; may consider 100–200 mg daily if patient requests, but not a substitute for rechallenge strategy.
Step 5: Special Populations and Monitoring
Hypertriglyceridemia Management:
- TG 150–499 mg/dL: lifestyle + statin (treat ASCVD risk)
- TG ≥ 500 mg/dL: fibrate or omega-3 fatty acids (icosapent ethyl 4 g/day per REDUCE-IT) to prevent pancreatitis
- Icosapent ethyl (Vascepa): indicated for TG 135–499 with ASCVD or diabetes + ≥ 2 risk factors, on statin → 25% RRR for MACE
Monitoring Schedule:
| Timepoint |
Action |
| Baseline |
Fasting lipid panel, hepatic panel, CK if symptomatic, HbA1c |
| 4–12 weeks post-initiation |
Fasting lipid panel; hepatic panel if symptomatic |
| Annual (on stable therapy) |
Fasting lipid panel; reassess risk factors |
| After any dose change |
Fasting lipid panel at 4–12 weeks |
Checkpoint B: Post-Draft Alignment (Mandatory)
- Is the patient correctly categorized by ASCVD risk group?
- Is the statin intensity appropriate for the risk category?
- Is the LDL-C at target, or is an escalation plan documented?
- Are risk-enhancing factors documented for borderline/intermediate risk patients?
- If statin intolerance is claimed, is the rechallenge protocol documented?
Quality Audit
Guidelines
- Every ASCVD patient should be on high-intensity statin therapy unless contraindicated — this is the single most impactful pharmacotherapy for secondary prevention.
- Do not use LDL-C thresholds as the sole criterion for initiating statins in primary prevention — the 10-year ASCVD risk score drives the decision.
- For patients with LDL ≥ 190 mg/dL, start high-intensity statin without risk calculation — this likely represents familial hypercholesterolemia.
- CAC score of 0 in intermediate-risk patients supports deferring statin therapy (low event rate) — but does not apply to patients with diabetes, ASCVD, or LDL ≥ 190.
- PCSK9 inhibitors provide large LDL reductions but should be reserved for patients who cannot reach target on maximally tolerated statin + ezetimibe — document prior authorization requirements.
- Statin intolerance requires objective documentation: ≥ 2 statin trials, symptom recurrence with rechallenge, and symptom resolution with discontinuation. Nocebo effect is common.
- Routine CK monitoring in asymptomatic patients on statins is not recommended — check only if muscle symptoms develop.
- Omega-3 fish oil supplements (non-prescription) do not have cardiovascular benefit at standard doses — only icosapent ethyl 4 g/day (prescription EPA) has trial-proven benefit.
1---2name: managing-lipid-therapy3description: Guides statin selection and intensity with ASCVD risk calculation and LDL targets. Use when managing lipids, calculating cardiovascular risk, or optimizing lipid-lowering therapy.4---5
6# Managing Lipid Therapy
7
8Guides statin selection and intensity with ASCVD risk calculation and LDL targets.
9
10## Why This Skill Exists
11
12Atherosclerotic cardiovascular disease (ASCVD) remains the leading cause of death globally. The 2018 AHA/ACC Cholesterol Guideline and 2022 ACC Expert Consensus Decision Pathway define a risk-based approach to lipid management, with LDL-C as the primary target. Landmark trials (4S, HPS, JUPITER, FOURIER, ODYSSEY) demonstrate that each 39 mg/dL reduction in LDL-C reduces major cardiovascular events by approximately 22%.
13
14Despite this, statin therapy remains underutilized — fewer than 50% of eligible patients receive appropriate-intensity statins, and escalation to ezetimibe, PCSK9 inhibitors, or bempedoic acid when LDL remains above target is inconsistent. This skill ensures systematic risk assessment, appropriate statin intensity selection, and evidence-based escalation when targets are not met.
15
16---
17
18## Checkpoint A: Pre-Draft Intake (Mandatory)
19
201. Does the patient have clinical ASCVD (prior MI, stroke, TIA, PAD, coronary revascularization)? (default: "ASCVD status not documented")
212. What is the fasting lipid panel — TC, LDL-C, HDL-C, triglycerides? (default: "Lipid panel not provided")
223. What is the patient's 10-year ASCVD risk score (Pooled Cohort Equations)? (default: "Not yet calculated")
234. Is the patient currently on lipid-lowering therapy? If so, which agent and dose? (default: "Current therapy not documented")
245. Are there statin-related side effects reported (myalgia, hepatotoxicity, new-onset DM)? (default: "No side effects reported")
256. What are the risk-enhancing factors — family history of premature ASCVD, LDL ≥ 160, metabolic syndrome, CKD, inflammatory conditions, ethnicity, Lp(a), hsCRP? (default: "Risk enhancers not assessed")
267. Has coronary artery calcium (CAC) scoring been performed? (default: "CAC not obtained")
278. Is the patient diabetic? Age range? (default: "Diabetes status not documented")
28
29### Documents to Request
30
31- Fasting lipid panel (recent, within 4–12 weeks of assessment)
32- Prior lipid panels for trend analysis
33- 10-year ASCVD risk score calculation
34- CAC score report if obtained
35- Current medication list
36- History of statin intolerance documentation
37- Lp(a) level if available
38- hsCRP if available
39- HbA1c (diabetes status)
40- Hepatic function panel (baseline before statin initiation)
41
42---
43
44## Step 1: Patient Risk Category Classification
45
46**2018 ACC/AHA Risk Groups:**
47
48| Risk Group | Definition | Primary Therapy |
49|-----------|-----------|----------------|
50| Clinical ASCVD | Prior MI, stroke, TIA, PAD, coronary revascularization | High-intensity statin; LDL < 70 |
51| Very high-risk ASCVD | ASCVD + multiple major events or high-risk conditions | Max statin + ezetimibe ± PCSK9i; LDL < 55 |
52| Severe hypercholesterolemia | LDL ≥ 190 mg/dL | High-intensity statin without risk calculation |
53| Diabetes (age 40–75) | DM + LDL 70–189 | Moderate-to-high intensity statin based on risk |
54| Primary prevention (age 40–75) | No ASCVD, no DM, LDL 70–189 | Based on 10-year ASCVD risk |
55
56**10-Year ASCVD Risk Thresholds (Primary Prevention):**
57
58| Risk Level | 10-Year Risk | Recommendation |
59|-----------|-------------|----------------|
60| Low | < 5% | Lifestyle; statin generally not indicated |
61| Borderline | 5–7.4% | Consider statin if risk enhancers present |
62| Intermediate | 7.5–19.9% | Moderate-intensity statin; consider CAC for shared decision-making |
63| High | ≥ 20% | High-intensity statin |
64
65**Risk-Enhancing Factors (tip the balance toward statin initiation):**
66- Family history of premature ASCVD (♂ < 55, ♀ < 65)
67- Persistently elevated LDL ≥ 160 mg/dL
68- Metabolic syndrome
69- CKD (eGFR 15–59)
70- Chronic inflammatory conditions (RA, psoriasis, HIV)
71- South Asian ancestry
72- Premature menopause (< 40 years)
73- Preeclampsia history
74- Lp(a) ≥ 50 mg/dL (or ≥ 125 nmol/L)
75- hsCRP ≥ 2.0 mg/L
76- ABI < 0.9
77
78---
79
80## Step 2: Statin Selection and Intensity
81
82**High-Intensity Statins (≥ 50% LDL reduction):**
83
84| Agent | Dose |
85|-------|------|
86| Atorvastatin | 40–80 mg |
87| Rosuvastatin | 20–40 mg |
88
89**Moderate-Intensity Statins (30–49% LDL reduction):**
90
91| Agent | Dose |
92|-------|------|
93| Atorvastatin | 10–20 mg |
94| Rosuvastatin | 5–10 mg |
95| Simvastatin | 20–40 mg |
96| Pravastatin | 40–80 mg |
97| Lovastatin | 40–80 mg |
98| Fluvastatin XL | 80 mg |
99| Pitavastatin | 1–4 mg |
100
101**Drug Interactions to Check:**
102- Simvastatin: contraindicated with strong CYP3A4 inhibitors (clarithromycin, itraconazole, HIV protease inhibitors); max 20 mg with amiodarone, amlodipine
103- Atorvastatin: dose limit with cyclosporine, clarithromycin, itraconazole
104- Rosuvastatin: preferred in patients on CYP3A4 inhibitors (metabolized by CYP2C9)
105- All statins: caution with gemfibrozil (rhabdomyolysis risk)
106
107---
108
109## Step 3: LDL-C Target Assessment and Escalation
110
111**LDL-C Targets by Risk Category:**
112
113| Category | LDL-C Target | Threshold for Adding Non-Statin |
114|----------|-------------|-------------------------------|
115| Very high-risk ASCVD | < 55 mg/dL | LDL ≥ 55 on max statin |
116| Clinical ASCVD | < 70 mg/dL | LDL ≥ 70 on max statin |
117| High-risk primary prevention (≥ 20%) | ≥ 50% LDL reduction | If not achieving ≥ 50% reduction |
118| Diabetes with risk factors | < 70 mg/dL | LDL ≥ 70 on statin |
119
120**Escalation Ladder (add sequentially if LDL not at target):**
1211. Maximize statin intensity (atorvastatin 80 mg or rosuvastatin 40 mg)
1222. Add ezetimibe 10 mg (additional 15–20% LDL reduction; IMPROVE-IT trial)
1233. Add PCSK9 inhibitor: evolocumab 140 mg SC q2 weeks or alirocumab 75–150 mg SC q2 weeks (additional 50–60% LDL reduction; FOURIER, ODYSSEY trials)
1244. Consider bempedoic acid 180 mg daily (additional 15–18% LDL reduction; CLEAR Outcomes trial) — particularly useful in statin-intolerant patients
1255. Consider inclisiran 284 mg SC (at months 0, 3, then q6 months) for sustained LDL lowering
126
127**Recheck lipid panel 4–12 weeks after any therapy change.**
128
129---
130
131## Step 4: Managing Statin Intolerance
132
133**True vs. Perceived Statin Intolerance:**
134- True myopathy: CK elevation > 10× ULN with symptoms → discontinue immediately
135- Statin-associated muscle symptoms (SAMS): myalgia without significant CK elevation → most common reason for discontinuation
136
137**Approach to SAMS:**
1381. Hold statin for 2–4 weeks (washout)
1392. Rechallenge with a different statin at low dose (rosuvastatin 5 mg or pravastatin 20 mg)
1403. Try alternate-day dosing (rosuvastatin or atorvastatin — long half-lives permit this)
1414. If intolerant to ≥ 2 statins: document as "statin-intolerant"
1425. Use non-statin therapies: ezetimibe ± bempedoic acid ± PCSK9i
143
144**CoQ10 supplementation:** Mixed evidence; may consider 100–200 mg daily if patient requests, but not a substitute for rechallenge strategy.
145
146---
147
148## Step 5: Special Populations and Monitoring
149
150**Hypertriglyceridemia Management:**
151- TG 150–499 mg/dL: lifestyle + statin (treat ASCVD risk)
152- TG ≥ 500 mg/dL: fibrate or omega-3 fatty acids (icosapent ethyl 4 g/day per REDUCE-IT) to prevent pancreatitis
153- Icosapent ethyl (Vascepa): indicated for TG 135–499 with ASCVD or diabetes + ≥ 2 risk factors, on statin → 25% RRR for MACE
154
155**Monitoring Schedule:**
156| Timepoint | Action |
157|-----------|--------|
158| Baseline | Fasting lipid panel, hepatic panel, CK if symptomatic, HbA1c |
159| 4–12 weeks post-initiation | Fasting lipid panel; hepatic panel if symptomatic |
160| Annual (on stable therapy) | Fasting lipid panel; reassess risk factors |
161| After any dose change | Fasting lipid panel at 4–12 weeks |
162
163---
164
165## Checkpoint B: Post-Draft Alignment (Mandatory)
166
1671. Is the patient correctly categorized by ASCVD risk group?
1682. Is the statin intensity appropriate for the risk category?
1693. Is the LDL-C at target, or is an escalation plan documented?
1704. Are risk-enhancing factors documented for borderline/intermediate risk patients?
1715. If statin intolerance is claimed, is the rechallenge protocol documented?
172
173---
174
175## Quality Audit
176
177- [ ] Fasting lipid panel documented with date
178- [ ] 10-year ASCVD risk score calculated (for primary prevention patients)
179- [ ] Risk category assigned per 2018 ACC/AHA guideline
180- [ ] Statin intensity matches risk category
181- [ ] LDL-C target identified and current level compared
182- [ ] Escalation plan documented if LDL not at target
183- [ ] Drug interactions checked for statin selection
184- [ ] Risk-enhancing factors assessed for borderline/intermediate risk
185- [ ] CAC scoring considered for shared decision-making in intermediate risk
186- [ ] Statin intolerance properly documented with rechallenge history
187- [ ] Hypertriglyceridemia assessed and treated if TG ≥ 500
188- [ ] Icosapent ethyl considered for eligible patients (REDUCE-IT criteria)
189- [ ] Follow-up lipid panel scheduled at appropriate interval
190- [ ] Lifestyle modifications (diet, exercise, weight) reinforced
191
192---
193
194## Guidelines
195
1961. Every ASCVD patient should be on high-intensity statin therapy unless contraindicated — this is the single most impactful pharmacotherapy for secondary prevention.
1972. Do not use LDL-C thresholds as the sole criterion for initiating statins in primary prevention — the 10-year ASCVD risk score drives the decision.
1983. For patients with LDL ≥ 190 mg/dL, start high-intensity statin without risk calculation — this likely represents familial hypercholesterolemia.
1994. CAC score of 0 in intermediate-risk patients supports deferring statin therapy (low event rate) — but does not apply to patients with diabetes, ASCVD, or LDL ≥ 190.
2005. PCSK9 inhibitors provide large LDL reductions but should be reserved for patients who cannot reach target on maximally tolerated statin + ezetimibe — document prior authorization requirements.
2016. Statin intolerance requires objective documentation: ≥ 2 statin trials, symptom recurrence with rechallenge, and symptom resolution with discontinuation. Nocebo effect is common.
2027. Routine CK monitoring in asymptomatic patients on statins is not recommended — check only if muscle symptoms develop.
2038. Omega-3 fish oil supplements (non-prescription) do not have cardiovascular benefit at standard doses — only icosapent ethyl 4 g/day (prescription EPA) has trial-proven benefit.
CaseMark